Removal of the “X-Waiver” Requirement

Overview

The recently passed 2023 Consolidation Appropriations Act (Act) took important steps forward in making buprenorphine for opioid use disorder easier to access. While significant barriers remain, these changes will likely improve access, decrease stigma, and encourage equitable access to treatment for all. This fact sheet outlines the history of buprenorphine regulation and the provisions included in the Act.